OpenAI has acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. OpenAI is bringing Orchestra’s team and technology together with Rosalind, its AI models and tools for life sciences research. The stated goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner.

Drug development is extraordinarily complex, taking roughly 10 to 15 years on average from target discovery to regulatory approval in the United States. Beyond science, teams must orchestrate programs across internal departments and external partners, often relying on disconnected systems. OpenAI says AI is at an inflection point where it can help take on these specialized tasks and complex workflows.

Rosalind brings OpenAI‘s AI models and tools to life sciences researchers. GPT-Rosalind helps scientists reason through questions in biology and chemistry, and Rosalind Workbench connects those capabilities with scientific tools and data to help researchers analyze results and plan experiments. Orchestra Bio brings a team with experience across biotech, software, and AI, along with a platform built to coordinate drug development. Together, the aim is to build agents that help teams connect scientific findings with the studies, decisions, and next steps needed to advance a potential medicine.

Orchestra Bio is a platform where people and AI agents work together to advance drug programs. Scientists and program leaders can delegate the monitoring and tracking of studies and campaigns to agents, freeing up time to guide the work, make decisions, and address issues before they cause delays. Since a problem in one part of a drug program can affect many others—a failed manufacturing batch can delay the start of a clinical trial—Orchestra’s agents help teams identify which activities and timelines are affected, gather the relevant information, and compare ways to respond.

The announcement also highlights existing collaborations: a partnership with Novo Nordisk aims to translate its scale and scientific expertise into faster R&D and commercial execution while maintaining strong governance, and at Moderna AI is helping teams translate insights from complex data into experimental workflows. OpenAI‘s vision is for AI to help scientists across the full process of discovering and developing new medicines, and it presents the Orchestra Bio acquisition as a step toward that vision.